Skip to content

Automated Oxygen Control by O2matic to Patients Admitted With Acute Hypoxemia

Automated Oxygen Control by O2matic to Patients Admitted With Acute Hypoxemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04079465
Acronym
O2MATIC-ACUT
Enrollment
30
Registered
2019-09-06
Start date
2019-10-01
Completion date
2023-12-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxemia, Hypoxemic Respiratory Failure, Hypoxia, Respiratory Failure, Respiratory Insufficiency

Keywords

closed-loop, oxygen treatment

Brief summary

The aim of this study is to examine if automated oxygen delivery with O2matic allows for faster weaning from oxygen supply and better oxygen control than manually controlled oxygen therapy for patients admitted to the emergency department with acute hypoxemia. Furthermore it will be tested if O2matic compared to manual control allows for earlier discharge.

Detailed description

Closed-loop control of oxygen therapy is described in the literature used for preterm infants, trauma patients, medical emergency use, and for patients with Chronic Obstructive Pulmonary Disease (COPD). O2matic is a closed-loop system that is based on continuous and non-invasive measurement of pulse rate and oxygen-saturation (SpO2). The algorithm in O2matic controls oxygen delivery with the aim of keeping the SpO2 within the desired interval, which could be 88-92 % for patients at risk of hypercapnia or 94-98 % for patients with pneumonia, asthma exacerbation, heart failure and other medical emergencies, according to guidelines from British Thoracic Society (BTS). SpO2-interval can be set for the individual patients, as can the range of acceptable oxygen-flow. If SpO2 or oxygen-flow cannot be maintained within the desired intervals an alarm will sound. All studies on closed-loop systems have shown that this method is better than manually control by nurse to maintain saturation within the desired interval. Furthermore, some studies have indicated that closed-loop has the possibility to reduce admission time and to reduce time spent with oxygen therapy, due to more efficient and faster withdrawal from oxygen supplementation. In the present study O2matic will be tested versus manual control, for patients admitted to the emergency department with acute hypoxemia due to any reason, except for carbon monoxide (CO) poisoning and other conditions where SpO2 is not a reliable measure of hypoxemia. During the study the patients will either have oxygen controlled with O2matic or manually by nursing staff for 24 hours or until discharge or weaning from oxygen supply. All patients will have continuous logging of pulse rate, oxygen-saturation and oxygen-flow with O2matic, but only in the O2matic active group, the algorithm will control oxygen-delivery. The primary hypothesis is that O2matic compared to manual control allows for faster weaning from oxygen supplementation, and that more patients will be weaned from oxygen supplementation within a time frame of 24 hours. Furthermore it will be tested if O2matic compared to manual control allows for earlier hospital discharge. It will be tested if O2matic is better than manual control in maintaining oxygen-saturation within the desired interval and reducing time with unintended hypoxia and hyperoxia. No safety issues has been reported in the literature. O2matic is approved in Europe with Conformité Européenne (CE) mark, and approved for clinical testing by The Danish Medicines Agency, The Ethics Committee in the Capital Region of Denmark and by the regional Data Protection Board. The study will be conducted according to Good Clinical Practice (GCP) standards with independent monitoring. All adverse events and serious adverse events will be monitored and serious adverse events will be reported to Danish Medicines Agency.

Interventions

DEVICEO2matic

O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.

Sponsors

Innovation Fund Denmark
CollaboratorINDIV
Hvidovre University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open label randomized controlled parallel study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admission with hypoxemic respiratory failure * Age \>= 18 years * Expected duration of admission \> 24 hours * Need for oxygen supplementation to maintain SpO2 \>= 88 % (patients at risk of hypercapnia) or SpO2 \>= 94 % (other patients) * Cognitively able to participate in the study * Willing to participate and give informed consent

Exclusion criteria

* Need or anticipated need for mechanical ventilation (intermittent Continuous Positive Airway Pressure (CPAP) is allowed) * Patients with CO-poisoning or other condition with unreliable SpO2. * Patients in need of oxygen supplementation at more than 10 liters/min * Pregnancy * Cognitive or language barriers for participation

Design outcomes

Primary

MeasureTime frameDescription
Probability of weaning from oxygen within 24 hours24 hoursFraction of patients weaned from oxygen supplementation within 24 hours

Secondary

MeasureTime frameDescription
Duration of admission30 daysTime from admission to emergency department to discharge from hospital
Time within SpO2 target interval24 hoursFraction of time within prescribed SpO2 interval in O2matic and manual arm
Probability of weaning from oxygen within 12 hours12 hoursFraction of patients weaned from oxygen supplementation within 12 hours
Time with severe hypoxemia24 hoursFraction of time with SpO2 at 4 or more percentage points below target interval
Time with hyperoxia24 hoursFraction of time with SpO2 above target interval in O2matic and manual arm
Time with minor hypoxemia24 hoursFraction of time with SpO2 at 1 to 3 percentage points below target interval

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026